First Quarter 2016 Earnings Call...First Quarter 2016 Earnings Call May 9, 2016 Forward-Looking...
Transcript of First Quarter 2016 Earnings Call...First Quarter 2016 Earnings Call May 9, 2016 Forward-Looking...
First Quarter 2016Earnings Call
May 9, 2016
Forward-Looking Statements
All of the statements in this presentation that are not statements of historicalfacts constitute forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Examples of such statements includefuture product development and regulatory events and goals, anticipatedclinical trial results and strategies, product collaborations, our businessintentions and financial estimates and results. These statements are basedupon management’s current plans and expectations and are subject to anumber of risks and uncertainties which could cause actual results to differmaterially from such statements. A discussion of the risks and uncertaintiesthat can affect these statements is set forth in the Company’s annual andquarterly reports filed from time to time with the Securities and ExchangeCommission under the heading “Risk Factors.” The Company disclaims anyintention or obligation to revise or update any forward-looking statements,whether as a result of new information, future events, or otherwise.
1
Our FocusTo discover, develop and commercialize
biopharmaceuticals that target the extracellular matrix and tumor
microenvironment
2
Two-Pillar Strategy For Growth
3
ENHANZE™ Platform PEGPH201 Platform
nCH2 CH2 OCH2 O
CH3
N
H
OCH2 CH2 OO CH2
CH3
NH
O
n
CH2 CH2 OO CH2CH3
N
O H
n
nCH2 CH2 OCH2 O
CH3
N
H
OCH2 CH2 OO CH2
CH3
N
O H
n
PEGylated form of rHuPH20
Licensing/Royalty Agreements Based On Proprietary Enzyme, rHuPH20
Investigational New Oncology DrugStudying pan-tumor potential
NOTE: 1) PEGPH20 is an investigational new drug Safety and efficacy profile have not been established; it is not currently available forcommercial distribution.
PEGPH20 Goal: Improve Targeting Of Co-Administered Cancer Therapies
4
5
HALO-301|Pancreatic: Phase 3 Design
• Randomized (2:1 PAG:AG), double-blind, placebo-controlled, global
• First patient dosed in March 2016, approximately 200 sites in 20 countries
• Interim analysis when target number of PFS events reached
• PFS powered with a hazard ratio of 0.59 (to detect a 41% risk reduction for progression)
PEGPH20 + ABRAXANE® + gemcitabine (PAG)
ABRAXANE® + gemcitabine (AG) + placebo
MetastaticPDA
High-HA patients
N=420
Primary Endpoints: Progression-Free Survival (PFS)Overall Survival (OS)
Studying Pan-Tumor Potential of PEGPH20
6
PEGPH20 Study
Preclinical Phase 1 Phase 2 Phase 3InCombination
withTumor
Gemcitabineand nab-Paclitaxel (Abraxane)
Pancreatic Cancer
Docetaxel(PRIMAL) NSCLC
Pembrolizumab(Keytruda®)
Gastric/ NSCLC
Eribulin(Halaven®)
BreastCancer(Eisai)
Additional Investigator Sponsored Trials in Pancreatic Cancer: SWOG, UCSF
Oncology Pipeline Update
7
PEG-ADA2 Program Highlights
8
Adenosine: Attractive immune checkpoint target
• Abnormally high levels accumulate in the TME • Binds to receptor checkpoints on immune cells• Contributes to an immunosuppressive TME
PEG-ADA2: An engineered human enzyme that targets adenosine
• Improved pharmacokinetics and enzyme activity• Anti-tumor responses observed in several animal
models− Increase in T-cell infiltration− Decrease in high TME adenosine levels
HTI-1511 Anti-EGFR ADC Program Highlights
9
Engineered mAb with attenuated binding to human skin grafts
ADC mechanism targets KRAS- or BRAF-mutated tumors in mice
Utilization of next generation, Thiobridge chemistry• More homogeneous, stable
Safety profile met criteria for candidate nomination
Complete tumor responses observed in PDx tumor models
IND enabling studies underway
ENHANZE™ Technology
10
ENHANZE: Our Novel Delivery Platform
Potential Benefits:• Facilitate transition of IV therapies to
subcutaneous administration• Reduce multiple injections• Enable large volume of biologics to
be delivered subcutaneously• Reduce time required for drug
administration• Life cycle management, including
potential patent life extension
11
Partner Target US /OUS Preclinical Phase 1 Phase 3 Approved
Herceptin SC OUS
Mabthera SC OUS
HYQVIA US
HYQVIA OUS
Daratumumab --
Rivipansel --
Bococizumab --
Humira --
3 Targets Identified --
ENHANZE: Our Novel Delivery Platform
12
ENHANZE Momentum: Partnerships Accelerating, Royalty Pipeline Building
13
$25M
$160M
5
$23M
$130M
9
$15M
$113M
5
$8M
$85M
6
$10M
$37M
1
$20M
$37-47M
8
Upfront
Milestones/ Target
Targets
• 2 new partnerships in 2015• Time from signing to clinic accelerating• 4 targets in clinic; new studies planned• Estimated 150 targets available that may benefit from ENHANZE
20152007 2012 20142006
Mid-single Digit Royalties on Net Sales
Roche Update: Herceptin SC1
14
1) Information provided during Roche investor update (Apr. 19, 2016).
Financial Update
15
1Q 2016 1Q 2015 % Change
Total Revenue $42.5 $18.7 128%
Royalty Revenue $11.4 $6.8 68%
Bulk rHuPH20 Sales $9.0 $6.1 48%
Hylenex® recombinant $3.9 $3.8 2%
Collaboration Revenue $18.2 $2.0 795%
First Quarter 2016 Financial Highlights1
$ U.S. in Millions (unaudited)
NOTE: 1) Dollar amounts and percentages, as presented, are rounded.
16
1Q 2016 1Q 2015 % Change
Total Revenues $42.5 $18.7 128%
Total Operating Expenses $58.7 $32.6 80%
Cost of Product Sales $7.8 $6.5 20%
R&D Expense $40.1 $16.7 140%
SG&A Expense $10.8 $9.4 15%
Net Loss ($19.8) ($15.1) --
EPS ($0.16) ($0.12) --
Cash and marketable securities $238.6 $128.5 --
First Quarter 2016 Financial Highlights1
$ U.S. in Millions, except EPS (unaudited)
NOTE: 1) Dollar amounts and percentages, as presented, are rounded.
17
Update: 2016 Financial Guidance
18
Previous Revised
Revenue $110M to $125M $130M to $145M
Operating Expenses $240M to $260M $245M to $260M
Cash Flow $35M to $55M $45M to $65M
Year-end Cash $140M to $160M $150M to $170M
Value Enhancing Milestones Throughout 2016
19
Goal Target Date
Initiate HALO-301|Pancreatic trial End of Q1 2016
HALO-Eisai Study in Breast Cancer Patients Initiated End of Q2 2016
Advance to Dose Expansion Phase in KEYTRUDA and PRIMAL Studies (pending number of dose cohorts)
2H 2016
Report mature data from HALO 202 | Pancreatic Q4 2016
Seek new ENHANZE collaboration and licensing agreements and support current partner clinical progress
2016
✓
First Quarter 2016Earnings Call
May 9, 2016